Retrospective Analysis of Smell and Taste Disturbances Associated with Dermatologic Medications Reported to the United States Food and Drug Administration and Relevance to COVID-19 Infections

The document discussed the potential link between androgenetic alopecia (AGA) and COVID-19 severity, noting that AGA might reflect higher androgen activity, a vulnerability factor for COVID-19. It mentioned ongoing clinical trials with bicalutamide, degarelix, and spironolactone. Limitations included sample size, lack of control group, and potential observer bias. The study suggested future research to explore correlations between lung involvement and AGA severity. The term "Gabrin sign" was proposed to identify patients at higher risk for severe COVID-19 symptoms, named after the first U.S. physician to die from the virus.